TGF-β2 silencing to target biliary-derived liver diseases
Anne Dropmann(University Hospital Heidelberg), Nadja M. Meindl‐Beinker(Heidelberg University), Ana Stojanovic(University of Mannheim), Shahrouz Ghafoory(Heidelberg University), Matthias Ebert(University of Mannheim), Stefanie Nittka(Heidelberg University), Thomas S. Weiß(Sigmund Freud Privatuniversität Wien), Hanna Korhonen(Heidelberg University), Timo Itzel(University Hospital Regensburg), Ulrich M. Zanger(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), John Brain(Newcastle upon Tyne Hospitals NHS Foundation Trust), Naiara Beraza(Quadram Institute), Adelheid Cerwenka(University of Mannheim), Steven Dooley(Heidelberg University), Katja Wosikowski(Isarna Therapeutics (Germany)), Małgorzata Milkiewicz(Pomeranian Medical University), Albrecht Piiper(Goethe University Frankfurt), Julia Werle(Charles University), Seddik Hammad(South Valley University), T. Dediulia(Heidelberg University), Piotr Milkiewicz(Medical University of Warsaw), Andreas Teufel(Johannes Gutenberg University Mainz), David Jones(Memorial Sloan Kettering Cancer Center), Michel Janicot(Sensata Technologies (Netherlands)), Detlef Schuppan(Beth Israel Deaconess Medical Center), Vanessa Hartwig(Heidelberg University), Timo Gaiser(University of Mannheim), Stefan Woelfl(Heidelberg University), Bedair Dewidar(Tanta University)
Cited by 43
Related Papers
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Serum markers detect the presence of liver fibrosis: A cohort study
|Gastroenterology|2004|1.1k